Use of an automated mobile application to assess effects of nicotine withdrawal on verbal fluency: A pilot study.
Mild-to-moderate impairment in frontally mediated functions such as sustained attention, working memory, and inhibition have been found to occur during tobacco withdrawal and may present a barrier to successful cessation. These findings have led to studies evaluating cessation treatments that target nicotine withdrawal related cognitive impairment. The instruments currently used to assess cognitive function provide detailed and specific information but have limitations including being time consuming, cumbersome, anxiety provoking, and having poor ecological validity. The authors examined the feasibility of using a mobile computer application to test verbal fluency (VF) as a quick, easy-to-administer, and more ecologically valid method of measuring the effects of short-term smoking abstinence on frontally mediated cognitive functions. Thirty participants completed 2 assessments-1 during ad lib smoking and 1 after overnight abstinence. At each assessment, semantic and phonemic VF tests were administered using a mobile application and nicotine craving and withdrawal symptom severity was assessed. In repeated assessments, performance on both semantic and phonemic VF tests is expected to improve due to practice effects; however, significant improvements were observed only in semantic (p = .012) but not phonemic (p = .154) VF. In addition, the change between assessments in phonemic (but not semantic) score was significantly associated with withdrawal (p = .006) and craving (p = .037) severity measured postabstinence. This study demonstrates that nicotine withdrawal has differential effects on semantic versus phonemic VF suggesting impairments of working memory, attention, and inhibition. These effects were measured using methods easily used in large groups of participants, potentially with remote test administration and automated scoring. (PsycINFO Database Record
Department of Pharmaceutical Care and Health Systems.
Serguei V S
SV
Pakhomov
College of Pharmacy, University of Minnesota.
Wrenda
W
Teeple
Department of Experimental and Clinical Pharmacology.
Anne M
AM
Mills
Department of Experimental and Clinical Pharmacology.
Michael
M
Kotlyar
D001184:Articulation Disorders / Q000175:diagnosis* / Q000209:etiology*; D003071:Cognition; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D063731:Mobile Applications; D009538:Nicotine / Q000009:adverse effects*; D010865:Pilot Projects; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*; D014705:Verbal Behavior / Q000502:physiology
D009538:Nicotine
Proc Biol Sci. 1996 Aug 22;263(1373):989-95
8805836
Speech Commun. 2015 Dec 1;75:14-26
26622073
J Clin Exp Neuropsychol. 1997 Aug;19(4):543-59
9342689
BMC Neurosci. 2010 Sep 16;11:118
20846444
J Int Neuropsychol Soc. 2006 Nov;12(6):896-900
17064451
Arch Neurol. 1994 Jul;51(7):653-60
8018037
Nicotine Tob Res. 2001 Feb;3(1):7-16
11260806
J Int Neuropsychol Soc. 2001 Sep;7(6):675-82
11575589
Clin Neuropsychol. 2012;26(4):543-70
22540222
Neuropsychology. 2005 Mar;19(2):243-52
15769208
Arch Gen Psychiatry. 1986 Mar;43(3):289-94
3954551
Neurology. 2000 Oct 10;55(7):934-9
11061247
Biol Psychiatry. 2009 Jan 15;65(2):144-9
18842256
Transl Psychiatry. 2016 Jan 19;6:e713
26784967
Neuropharmacology. 2014 Jan;76 Pt B:581-91
23639437
J Clin Psychopharmacol. 2008 Dec;28(6):667-74
19011436
Eur J Neurol. 2013 Jan;20(1):130-7
22827489
Psychopharmacology (Berl). 2013 Sep;229(1):133-40
23591603
Arch Clin Neuropsychol. 2006 Apr;21(3):217-27
16554143
Arch Clin Neuropsychol. 2007 May;22(4):475-88
17317094
Neuropsychol Rehabil. 2003 Jul;13(3):365-78
21854318
Psychopharmacology (Berl). 2007 Mar;190(4):457-67
17205318
J Int Neuropsychol Soc. 1998 Nov;4(6):547-58
10050359
Neuropsychopharmacology. 2008 Feb;33(3):588-98
17443125
Arch Clin Neuropsychol. 1996;11(4):329-38
14588937
Neuropsychologia. 2009 Feb;47(3):652-6
19084028
Appl Neuropsychol. 2001;8(4):218-23
11989725
Arch Clin Neuropsychol. 1999 Feb;14(2):167-77
14590600
Addiction. 2006 Mar;101(3):362-72
16499509
Am J Geriatr Psychiatry. 2011 Nov;19(11):932-9
22024617
Biol Psychiatry. 2002 Jan 15;51(2):151-63
11822994
Neuropsychology. 2004 Oct;18(4):621-8
15506829
Arch Clin Neuropsychol. 2000 Apr;15(3):185-204
14590548
Int J Geriatr Psychiatry. 2009 Aug;24(8):885-93
19296551
Neuropsychology. 2004 Apr;18(2):284-95
15099151
Appl Neuropsychol. 2008;15(2):97-106
18568601
Alzheimer Dis Assoc Disord. 2004 Jul-Sep;18(3):120-2
15494616
Cereb Cortex. 2009 Nov;19(11):2690-8
19293396
Arch Clin Neuropsychol. 2005 Jun;20(4):517-29
15896564
Br J Clin Psychol. 2000 Jun;39 ( Pt 2):181-91
10895361
Expert Opin Drug Discov. 2014 Jun;9(6):579-94
24707983
Epilepsy Behav. 2012 Jul;24(3):365-72
22658432
Neuropsychologia. 2004;42(9):1212-22
15178173
J Int Neuropsychol Soc. 2004 Jul;10(4):608-22
15327739
Clin Neuropsychol. 2001 Feb;15(1):125-8
11778573
Biol Psychiatry. 2010 Apr 15;67(8):715-21
20207347
Exp Clin Psychopharmacol. 2012 Feb;20(1):63-70
21942262
Cogn Neuropsychiatry. 2005 Jan;10(1):1-33
16571449
Psychopharmacology (Berl). 2004 Sep;175(3):374-81
15114432
Addiction. 1997 Dec;92(12):1773-82
9581009
J Clin Psychol. 1990 Sep;46(5):628-31
2246371